Seeking Alpha

williamcarswell

williamcarswell
Send Message
View as an RSS Feed
View williamcarswell's Comments BY TICKER:
Latest  |  Highest rated
  • Is Starbucks A Good Dividend Pick? [View article]
    I agree with your point, but I don't think there's any serious question that SBUX has the financial strength to continue to expand AND grow the div. You can expect that over time, a consistently growing dividend will add handsomely to the total return.
    Apr 11 07:50 PM | Likes Like |Link to Comment
  • Theravance: Baby Thrown Out With The Bath Water - 35% To 65% Upside [View article]
    Do you believe THRX share price weakness is merely a reflection of weakness in the whole biotech sector, or rather, the fact that GSK's reported sales of Breo have been very weak? This risk doesn't seem to get the attention it needs.
    Mar 31 08:15 PM | 1 Like Like |Link to Comment
  • OPAP Has Significant Upside As The Greek Economy Stabilizes [View article]
    How much is the dividend amount going forward? Any ideas?
    Mar 2 12:28 PM | Likes Like |Link to Comment
  • Enanta's Abbvie Partnership Is Going Places But It's Still Overvalued [View article]
    Still waiting.
    Mar 1 11:27 PM | Likes Like |Link to Comment
  • J.C. Penney: New Hires, Short Groupthink, And No Borrow Means No Borrow Part II [View article]
    "Groupthink"? I thought that was when Ackman, et al. piled in, claiming the stock was worth $200, and believing Big Johnson was a retailing genius?
    Feb 17 12:08 PM | Likes Like |Link to Comment
  • J.C. Penney: Attempting A Reasonable Bullish Argument [View article]
    Ron Johnson was not given enough time. Had he been allowed to fully roll out yoga classes and iPad check out at JCP, the whole scenario would be different today.
    Feb 7 02:04 PM | 1 Like Like |Link to Comment
  • Enanta's Abbvie Partnership Is Going Places But It's Still Overvalued [View article]
    Are you going to correct this article?
    Feb 2 12:18 AM | Likes Like |Link to Comment
  • J.C.Penney: A Case Study In Poor IR, Time For Ullman To Step Down [View article]
    Electronics and a snack bar? You're kidding, right?
    Feb 1 04:33 PM | Likes Like |Link to Comment
  • Special Situations Alert: Details Behind Why I Bought NuPathe Inc. [View article]
    Your article doesn't mention that the rights are non-tradeable, an important consideration for many, because it doesn't allow one to change one's opinion on the investment. Once you get this right, it's yours until it pays or becomes worthless.
    Jan 28 08:53 AM | 1 Like Like |Link to Comment
  • Should You Gamble On Tropicana Entertainment? [View article]
    Whopper, an update would be great.
    Jan 1 03:11 PM | Likes Like |Link to Comment
  • Best Ideas For 2014: Long GCVRZ [View article]
    Yes. The specific terms of the security are outlined in CELG's 2010 S-4 issued for their purchase of Abraxis. This is available on EDGAR. Essentially, CELGZ works like this: the holders got a $6.93 per share milestone payment in October as a result of Abraxane being approved to treat pancreatic cancer on Sept 6, 2013.

    Following this, CELGZ will be entitled to a royalty based on annual sales of Abraxane which exceed $1 billion. No royalty in years below $1 bil. Note that they should do $600 million in calendar 2013 with pancreatic sales only beginning to ramp up in 4q13 (Abraxane was already approved for breast and lung cancers). These royalties run to 2025, but may be extended to 2030 as long as Abraxane sales exceed $1billion per annum. I expect $1bil+ in sales in CY2014 as it will have a full year of pancreatic sales.

    Also, tests are underway which evaluate Abraxane's use on melanoma. Obviously, this would add to sales and, thus, the royalty.

    I own this and have traded in and out quite successfully.
    Dec 21 07:05 PM | 1 Like Like |Link to Comment
  • Best Ideas For 2014: Long GCVRZ [View article]
    I think that while Lemtrada has promise as a drug, the structure of GCRVZ is problematic for the calendar issues Alpha Exposure raised.

    As far as CVRs go, I prefer CELGZ as a vastly superior investment with a nearly two decade royalty stream on CELG's recently approved Abraxane drug
    Dec 21 04:01 PM | Likes Like |Link to Comment
  • Rangeley Capital Best Investment Idea Outcomes [View instapost]
    And with Abraxane momentum strong, CELGZ still has a great deal of upside from here.
    Nov 23 03:31 PM | 1 Like Like |Link to Comment
  • AMR Corporation Is A Bargain [View article]
    Tom,
    I note the current price just shy of $12 is at quite a discount to the almost $15 value implied by a $23 LCC price. I recognize that a time discount is warranted, but since closing of the merger is now indicated for next month doesn't the discount appear rather steep? I also recognize that complete payout will take 120 days post effective date yet 25% seems excessive given the imminent closing of the deal. What am I missing?
    Nov 13 04:49 PM | Likes Like |Link to Comment
  • Should You Gamble On Tropicana Entertainment? [View article]
    TPCA rocking toward $20. Any news?
    Oct 18 04:42 PM | Likes Like |Link to Comment
COMMENTS STATS
62 Comments
25 Likes